Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MINIZIDE vs ALDORIL D30
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Prazosin is a selective alpha-1 adrenergic antagonist that inhibits vascular smooth muscle contraction, reducing peripheral vascular resistance and blood pressure. Polythiazide is a thiazide diuretic that inhibits the Na+/Cl- cotransporter in the distal convoluted tubule, increasing sodium and water excretion, and reducing intravascular volume.
Aldoril D30 is a combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, decreasing plasma volume and peripheral resistance.
Hypertension
Hypertension
1-2 capsules orally twice daily; each capsule contains prazosin 0.5 mg and polythiazide 0.5 mg. Titrate based on blood pressure response.
Oral: 1 tablet (hydrochlorothiazide 30 mg / methyldopa 500 mg) twice daily; maximum dose: 2 tablets twice daily.
2-3 hours (prazosin component); prolonged in heart failure or renal impairment
Terminal elimination half-life of hydrochlorothiazide is 6-15 hours; methyldopa half-life is 1.8 hours (normal renal function). In renal impairment, half-life of both components is prolonged.
Prazosin is extensively metabolized in the liver via O-demethylation and conjugation, primarily by CYP3A4. Polythiazide is not extensively metabolized; it is excreted unchanged in the urine.
Methyldopa is metabolized by conjugation (catechol-O-methyltransferase) and hepatic sulfation; hydrochlorothiazide is not extensively metabolized and is excreted unchanged by the kidney.
Renal: 90% (unchanged drug and metabolites); biliary/fecal: <10%
Renal: approximately 50% as parent drug and metabolites; biliary/fecal: minimal, less than 5%.
97% (prazosin bound to alpha-1 acid glycoprotein and albumin)
Methyldopa: <10% bound to plasma proteins; hydrochlorothiazide: 40-68% bound to albumin.
0.6 L/kg (prazosin); reflects extensive tissue distribution
Methyldopa: Vd 0.2-0.3 L/kg (distributes into tissues, crosses placenta); hydrochlorothiazide: Vd 0.75-1.5 L/kg (extensively distributed, does not cross blood-brain barrier significantly).
Oral: 50-70% (prazosin); first-pass metabolism reduces systemic availability
Oral bioavailability of methyldopa is approximately 25% (variable, influenced by gut metabolism); hydrochlorothiazide bioavailability is 65-75%.
Contraindicated in patients with GFR <30 m L/min. For GFR 30-60 m L/min: use with caution, reduce dose by 50%, monitor electrolytes. No adjustment for GFR >60 m L/min.
GFR 30-60 m L/min: reduce dose by 50%; GFR <30 m L/min: not recommended.
Child-Pugh A: no adjustment necessary. Child-Pugh B: reduce dose by 50%. Child-Pugh C: avoid use due to risk of hepatic encephalopathy.
Child-Pugh Class B or C: contraindicated; use not recommended.
Not recommended for pediatric use due to lack of safety and efficacy data.
Not recommended for use in pediatric patients due to lack of safety and efficacy data.
Initiate therapy at the lower end of the dosing range (1 capsule daily) due to increased sensitivity to orthostatic hypotension and electrolyte disturbances. Titrate slowly.
Start with lowest dose; monitor for hypotension, electrolyte imbalance, and CNS effects; consider reduced initial dose.
None.
None
First-dose syncope (orthostatic hypotension) can occur, especially with initial use or dose escalation,Sodium and water depletion may occur with thiazide, leading to hypokalemia, hyponatremia, and hypomagnesemia,May exacerbate renal impairment; monitor renal function,May increase serum uric acid and precipitate gout,May cause hypersensitivity reactions, including anaphylaxis and angioedema
May cause hemolytic anemia, liver disorders, positive Coombs test, sedation, depression, and hypersensitivity reactions. Hydrochlorothiazide may cause electrolyte imbalance, hyperuricemia, photosensitivity, and exacerbation of systemic lupus erythematosus. Use with caution in renal impairment, hepatic disease, and in patients with a history of drug-induced hemolytic anemia.
Anuria,Hypersensitivity to prazosin, polythiazide, or sulfonamide-derived drugs (thiazides),Concomitant use with phosphodiesterase-5 inhibitors (e.g., sildenafil) due to risk of severe hypotension
Active hepatic disease, history of previous methyldopa therapy-associated liver disorders; anuria; hypersensitivity to methyldopa, hydrochlorothiazide, or sulfonamide-derived drugs.
Avoid high-potassium foods (e.g., bananas, oranges) if potassium-sparing diuretics or supplements are used; hydrochlorothiazide can cause hypokalemia so potassium-rich foods may be recommended. Grapefruit juice may increase prazosin levels; avoid.
Food may decrease absorption of methyldopa. Avoid excessive intake of high-potassium foods (e.g., bananas, oranges) unless directed. Hydrochlorothiazide may cause potassium depletion; maintain adequate dietary potassium. Avoid natural licorice as it can worsen hypokalemia.
Prazosin-polythiazide combination. First trimester: Risk category C; limited human data. Second and third trimesters: potential fetal/neonatal effects include hypotension, electrolyte imbalance, and decreased placental perfusion. Avoid use unless clearly needed.
First trimester: Limited data; no clear evidence of major malformations but methyldopa crosses placenta. Second and third trimesters: Associated with reduced placental perfusion; possible fetal bradycardia and neonatal hypotension. Hydrochlorothiazide may cause fetal/neonatal jaundice, thrombocytopenia, and electrolyte disturbances.
Prazosin: low levels in breast milk; M/P ratio 0.75-1.0. Polythiazide: may suppress lactation; M/P ratio unknown. Use caution, monitor infant for diuretic effects or hypotension.
Methyldopa is excreted in breast milk in low concentrations; M/P ratio approximately 0.2. Hydrochlorothiazide is excreted in minimal amounts; may suppress lactation. Consider risks versus benefits.
Increased plasma volume and renal clearance may reduce drug levels; consider monitoring therapeutic effect and adjust dose accordingly. No fixed dosing guidelines; cautious titration recommended.
Methyldopa: Pregnancy-induced plasma volume expansion may require dose titration; monitor blood pressure and adjust accordingly. Hydrochlorothiazide: Often avoided in pregnancy due to volume depletion risks; if used, monitor electrolytes and renal function, no pharmacokinetic data necessitate routine dose adjustment.
MINIZIDE (prazosin/hydrochlorothiazide) is a fixed-dose combination for hypertension. Prazosin causes first-dose syncope; start with 1 mg at bedtime. Hydrochlorothiazide may cause hypokalemia; monitor potassium. Use cautiously in patients with history of angioedema from ACE inhibitors as prazosin may also cause angioedema.
ALDORIL D30 combines methyldopa (central alpha-2 agonist) and hydrochlorothiazide (thiazide diuretic). Monitor for orthostatic hypotension, especially at initiation. Taper not needed for methyldopa but discontinue if fever or liver dysfunction occurs. Interferes with urinary catecholamine measurements (false elevation). Hydrochlorothiazide may cause hyponatremia, hypokalemia, and hyperglycemia; check electrolytes and glucose periodically.
Take first dose at bedtime to avoid fainting.,Rise slowly from sitting or lying to prevent dizziness.,Avoid alcohol as it may worsen side effects.,Report episodes of fainting or rapid heartbeat.,Do not stop abruptly; may cause rebound hypertension.
Take exactly as prescribed, preferably with food to reduce stomach upset.,Rise slowly from sitting or lying down to prevent dizziness.,This drug may make you drowsy; avoid driving or operating machinery until you know how it affects you.,Report fever, unexplained fatigue, jaundice, or dark urine immediately.,Weigh yourself daily and report rapid weight gain or swelling.,Limit alcohol intake as it can increase side effects.,Do not use salt substitutes containing potassium without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MINIZIDE vs ALDORIL D30, answered by our medical review team.
MINIZIDE is a Antihypertensive Combination that works by Prazosin is a selective alpha-1 adrenergic antagonist that inhibits vascular smooth muscle contraction, reducing peripheral vascular resistance and blood pressure. Polythiazide is a thiazide diuretic that inhibits the Na+/Cl- cotransporter in the distal convoluted tubule, increasing sodium and water excretion, and reducing intravascular volume.. ALDORIL D30 is a Antihypertensive Combination that works by Aldoril D30 is a combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, decreasing plasma volume and peripheral resistance.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MINIZIDE and ALDORIL D30 depend on the specific clinical indication. These are both Antihypertensive Combination agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MINIZIDE is: 1-2 capsules orally twice daily; each capsule contains prazosin 0.5 mg and polythiazide 0.5 mg. Titrate based on blood pressure response.. The standard adult dose of ALDORIL D30 is: Oral: 1 tablet (hydrochlorothiazide 30 mg / methyldopa 500 mg) twice daily; maximum dose: 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MINIZIDE and ALDORIL D30 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MINIZIDE is classified as Category C. Prazosin-polythiazide combination. First trimester: Risk category C; limited human data. Second and third trimesters: potential fetal/neonatal effects include hypotension, electrol. ALDORIL D30 is classified as Category C. First trimester: Limited data; no clear evidence of major malformations but methyldopa crosses placenta. Second and third trimesters: Associated with reduced placental perfusion; p. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.